GlassScriptPhysician profile
Damien L Covington
NPI 1316912991
$10,798.97
in general payments reported to CMS, 2019-2025
44 companies · $977 in 2025
The $977 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,713 · 2020: $1,369 · 2021: $2,306 · 2022: $1,946 · 2023: $1,706 · 2024: $783 · 2025: $977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,406 · Education: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,406.24 |
| Education | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,036.23 | 2019-2025 | |
| Abbvie INC. | $1,001.32 | 2021-2025 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $879.91 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $864.52 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $687.06 | 2021-2025 | |
| Glaxosmithkline, LLC. | $610.98 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $562.55 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $512.72 | 2019-2025 | |
| Amgen INC. | $430.96 | 2019-2024 | Otezla, Repatha |
| Valeritas, INC. | $311.38 | 2019 | |
| Vanda Pharmaceuticals INC. | $250.72 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $247.32 | 2019-2022 | |
| Allergan, INC. | $245.93 | 2020 | |
| Astellas Pharma US INC | $235.33 | 2020-2025 | Veozah |
| Shield Therapeutics INC | $224.92 | 2022-2025 | Accrufer |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Damien Covington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.